Table 2.
Description of the final cohort at the time of enrolment (N = 10 184)
| Characteristic | N (%) | |||
|---|---|---|---|---|
| Demographic factors | Age in years | <16 | 85 (0.8) | |
| 16–44 | 3423 (33.7) | |||
| 45–64 | 5934 (58.4) | |||
| 65+ | 718 (7.1) | |||
| Missing | 24 (0.2) | |||
| mean age (SD) | 48.5 (11.7) | |||
| Gender | Female | 2950 (29.0) | ||
| Male | 7190 (70.6) | |||
| Other/missing | 44 (0.4) | |||
| Ethnic group | White | 8496 (83.4) | ||
| Asian/Asian British | 1004 (9.9) | |||
| Black/African/Caribbean/Black British | 223 (2.2) | |||
| Mixed/multiple ethnic groups | 103 (1.0) | |||
| Other | 256 (2.5) | |||
| Unknown | 102 (1.0) | |||
| Country of birth | UK | 7391 (72.6) | ||
| non-UK | 2591 (25.4) | |||
| NK/missing | 202 (2.0) | |||
| Hepatitis C infection factors | Route of infection/ risk group | Injecting drug use | 5290 (51.9) | |
| Blood transfusion/blood products | 1158 (11.8) | |||
| Born abroad | 1006 (9.9) | |||
| Sexual transmission | 335 (3.3) | |||
| Perinatal transmission | 98 (1.0) | |||
| Other | 1074 (10.6) | |||
| No known risk factor | 657 (6.5) | |||
| Missing | 566 (5.6) | |||
| Estimated duration of infection* | <20 yrs | 2840 (27.9) | ||
| 20yrs+ | 4214 (41.4) | |||
| unknown | 3130 (30.7) | |||
| Median duration, years (IQR) | 24 (13–32) | |||
| Genotype | 1 | 4770 (46.8) | ||
| 2 | 446 (4.4) | |||
| 3 | 3646 (35.8) | |||
| 4,5,6 | 338 (3.3) | |||
| Mixed genotype | 14 (0.1) | |||
| Missing/NK | 970 (9.5) | |||
| Clinical factors | Antiviral treatment history | Never treated | 4002 (39.3) | |
| Currently being treated | 1511 (14.8) | |||
| Previously treated and cleared infection (i.e. SVR) | 1366 (13.4) | |||
| Previously failed treatment (i.e. non-SVR) | 2947 (28.9) | |||
| Missing/NK | 358 (3.5) | |||
| Liver-related consequences of hepatitis C infection | Diagnosed with liver cirrhosis | No | 7803 (76.6) | |
| Yes - compensated cirrhosis | 1851 (18.2) | |||
| Yes - decompensated cirrhosis | 530 (5.2) | |||
| Diagnosed with liver cancer | No | 9981 (98.0) | ||
| Yes | 203 (2.0) | |||
| Prior liver transplantation | No | 9674 (95.0) | ||
| Yes | 495 (4.9) | |||
| Unknown | 15 (0.2) | |||
| All patients | 10184 | |||
*For individuals who acquired their infection via injecting drug use, the duration of infection was estimated by subtracting the year of enrolment into HCV Research UK from the year of first injection. We then subtracted a further 3 years from this, which relates to the average time from commencing injecting drug use to acquiring HCV infection (Hagan et al, Epidemiology. 2004;15(5):543–9).